Not a single study
Story checked
OnDosis and Adare Pharma Solutions announce strategic collaboration to advance OnDosis's lead U.S. ADHD program (opens in a new tab)
news-medical.net · 2026-10-01
Short answer
Not a single studyNo clear answer.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
OnDosis and Adare Pharma Solutions announce strategic collaboration to advance OnDosis's lead U.S. ADHD program
news-medical.net · 2026-10-01
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
This story isn't reporting one study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Open claim evidenceSearch result
No single source study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 3Not checkedOnDosis and Adare Pharma Solutions announced a strategic collaboration.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 3Not checkedAdare will provide CDMO services to support OnDosis's lead U.S. ADHD program, described as an extended-release oral pellet product containing mixed amphetamine salts delivered through OnDosis's Dosage Manager platform for individualized dosing.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 3Not checkedThe collaboration is meant to support the final steps to pivotal bioequivalence studies and a subsequent 505(b)(2) submission for OnDosis's lead product, Imfocy®, with the goal of improving outcomes for patients treated for ADHD.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Europe PMC, Crossref · 15 candidate papers
Safety, efficacy and extended duration of action of mixed amphetamine salts extended-release capsules for the treatment of ADHD.
Expert Opinion on Pharmacotherapy · 2005 · PubMed, Europe PMC, Crossref
Mixed Amphetamine Salts Extended Release for the Treatment of ADHD
CNS Spectrums · 2005 · Crossref
Safety and effectiveness of methylphenidate ER multi-unit pellet system in ADHD patients: An open label study.
2024 · Europe PMC
How Missing a Treatment of Mixed Amphetamine Salts Extended Release Affects Performance in Teen Drivers with ADHD
Driving Assessment Conference 2013 · 2013 · Crossref
Pharmacological validation of a translational model of cocaine use disorder: Effects of d-amphetamine maintenance on choice between intravenous cocaine and a nondrug alternative in humans and rhesus monkeys.
2020 · Europe PMC
And 10 more candidates considered.